Main Article Content
Clinical trials have shown that anti-tumour necrosis factor (TNF)-α drugs are effective in patients with rheumatoid arthritis (RA) refractory to disease- modifying antirheumatic drugs (DMARDs) (1-4). At about the same time as the European approval of the third anti-TNFα agent (adalimumab) for treating RA patients, the Italian Society of Rheumatology (Società Italiana di Reumatologia [SIR]) started a database for the registration and active follow-up of RA patients treated with biological response modifiers, which contains all of the demographic and clinical parameters, as well as the therapeutic data, usually needed to follow RA patients...
Downloads month by month
Download data is not yet available.